Alexion Pharmaceuticals Inc. revealed on 5 May that it has agreed to acquire Portola Pharmaceuticals Inc. for about $1.4bn in cash, but analysts don’t see the value in that price or in Portola’s Factor Xa inhibitor reversal drug Andexxa, a product stuck in neutral more than a year past its initial launch.
Alexion Buys Out Portola, But Analysts Don’t See Value
The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio – but analysts are struggling to see the match with Alexion’s chronic rare disease therapies.
